admin – Page 3244 – Get News Story

Denis Jesus Palma Abanto Talks about Smart Investment Ideas for Building Wealth

Denis Jesus Palma Abanto is an entrepreneur, software engineer, and angel investor known for his significant contributions to the tech and investment sectors. He completed his education from ESAN and London school of Business. He has worked with multiple companies like Telefonica, Trilogy, Solana Labs, Pixel Labs and now serving as a Chief Officer Executive at Belviera Inmobiliaria. Denis built all of Solana’s infrastructure from scratch during his tenure in early 2021. Denis has interest and expertise in multiple areas from blockchain infrastructure, security solutions, site reliability, Solana ecosystem to Investment.

Denis Jesus Palma Abanto

Investing is one of the most effective ways to build wealth, secure your financial future, and achieve long-term financial goals. Whether you’re a beginner or an experienced investor, staying updated on smart investment ideas can help you make informed decisions and optimize returns. Now, with global economic shifts, technological advancements, and evolving market trends, it’s important to adopt a balanced and diversified investment approach. Denis Jesus Palma Abanto explores a range of investment ideas across asset classes and strategies to help you grow your wealth.

1. Stock Market Investments

The stock market remains one of the most popular and potentially lucrative investment options. Investors can choose from individual stocks, mutual funds, or exchange-traded funds (ETFs) depending on their risk tolerance and investment goals.

a. Growth Stocks

Growth stocks represent companies with above-average revenue and earnings growth. Sectors like artificial intelligence, renewable energy, biotechnology, and cloud computing are poised for expansion. Companies like Nvidia, Tesla, or lesser-known AI startups could offer significant upside for long-term investors.

b. Dividend Stocks

Dividend-paying stocks provide regular income and are often more stable. Blue-chip companies like Johnson & Johnson or Coca-Cola offer consistent dividends, making them ideal for conservative investors or retirees looking for passive income.

c. ETFs and Index Funds

For diversification with lower risk, ETFs and index funds are excellent choices. Funds like the S&P 500 ETF (SPY) or Nasdaq-100 ETF (QQQ) give investors exposure to a broad range of top-performing companies, making them suitable for hands-off, long-term strategies.

2. Real Estate

Real estate continues to be a reliable investment, offering both capital appreciation and rental income. With rising urbanization and changing housing needs, several options are gaining popularity:

a. Residential Rental Properties

Owning rental homes or apartments can generate steady cash flow, especially in high-demand areas. Consider cities with growing populations, strong job markets, and a shortage of affordable housing.

b. Real Estate Investment Trusts (REITs)

REITs allow you to invest in real estate without owning physical property. Publicly traded REITs offer liquidity and regular dividends. REITs focused on logistics, data centers, and healthcare facilities are particularly promising.

3. Green and Sustainable Investments

As climate change awareness grows, sustainable investing is gaining traction. Environmental, Social, and Governance (ESG) investing focuses on companies with strong ethical practices.

a. Clean Energy Stocks

Companies involved in solar, wind, and hydrogen energy are set to benefit from global green initiatives. Consider stocks like First Solar or ETFs like iShares Global Clean Energy ETF (ICLN).

b. ESG Funds

Many mutual funds and ETFs now screen investments based on ESG criteria. These funds are ideal for investors looking to make a positive impact while generating returns.

4. Precious Metals and Commodities

Precious metals like gold and silver are traditional safe-haven assets. They tend to perform well during times of economic uncertainty or market volatility. Investors can buy physical bullion, ETFs like SPDR Gold Shares (GLD), or invest in mining stocks.

Commodities like oil, natural gas, and agricultural products can also be part of a diversified portfolio, especially as global supply chains shift and demand fluctuates.

5. Fixed Income and Bonds

Bonds offer stability and predictable income, making them ideal for conservative investors or those nearing retirement.

a. Treasury Bonds

U.S. Treasury bonds are backed by the federal government and offer low risk. As interest rates stabilize, long-term bonds could become attractive again.

b. Corporate Bonds

Corporate bonds from creditworthy companies provide higher yields than government bonds. However, investors should assess credit risk and duration carefully.

6. Alternative Investments

Alternative assets like hedge funds, private equity, art, collectibles, and even farmland are gaining popularity among high-net-worth individuals. These can provide uncorrelated returns and act as a hedge against traditional market risks, but they often require higher capital and longer investment horizons.

Successful investing requires a blend of traditional wisdom and modern innovation. The key is to align your investment choices with your financial goals, risk tolerance, and time horizon. Diversification—spreading your investments across various asset classes—is the cornerstone of a resilient portfolio. Whether you’re exploring stocks, real estate, or sustainable options, a well-researched and disciplined approach can help you navigate market uncertainties and build lasting wealth.

Denis Jesus Palma Abanto suggests considering consulting with a financial advisor before making significant investment decisions. Markets evolve, but with the right strategies, your investments can grow with them.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Belviera Inmobiliaria
Contact Person: Denis Jesus Palma Abanto
Email: Send Email
Country: Peru
Website: https://denis.pe

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Denis Jesus Palma Abanto Talks about Smart Investment Ideas for Building Wealth

New Book Arms Parents for the Courtroom: “Preparing for the Child Custody War” Offers Vital Strategy, Legal Insight, and Hope

“With family courtrooms in Georgia becoming increasingly complex, this powerful resource delivers the clarity and strategy parents need to protect their parental rights and advocate for their children’s best interests. This is not just another legal guide—it’s a roadmap for navigating the emotional, procedural, and legal minefields of custody disputes.”

From Mediation to Trial—A Practical Survival Manual for High-Stakes Custody Cases

Atlanta, GA – May 19, 2025 – In a groundbreaking release, legal professionals Genghis Shakhan and Chelsea Wilkerson unveil Preparing for the Child Custody War: Win the Battle and the War, an indispensable guidebook for parents facing one of life’s most emotionally taxing challenges—child custody battles. With family courtrooms in Georgia becoming increasingly complex, this powerful resource delivers the clarity and strategy parents need to protect their parental rights and advocate for their children’s best interests. This is not just another legal guide—it’s a roadmap for navigating the emotional, procedural, and legal minefields of custody disputes. “Custody isn’t just a legal issue—it’s a deeply personal one,” says co-author Genghis Shakhan. “This book equips parents with both the knowledge and emotional resilience they’ll need when everything is at stake.”

Key Topics Include:

Understanding Georgia’s “Best Interest of the Child” standard
How to prepare for Guardian ad Litem investigations
What to expect from custody evaluators and DFCS involvement
Trial preparation, mediation strategy, and post-judgment actions
How to handle Juvenile Court referrals and high-conflict cases

Unlike other custody books that skim the surface, Preparing for the Child Custody War dives deep into the realities of Georgia family law while offering real-world advice from seasoned experts. The authors break down complex topics into practical, accessible steps for both represented and self-represented parents.

Who Should Read This Book?

Divorcing or unmarried parents involved in Georgia custody cases.
Family law attorneys seeking a clear and comprehensive client resource.
Anyone facing DFCS investigations or court-ordered evaluations.
Parents preparing for trial, mediation, or developing parenting plans.

This book is more than preparation—it’s empowerment.

Preparing for the Child Custody War: Win the Battle and the War is soon available on Amazon in paperback and Kindle formats.

Order your copy today and take control of your custody journey: Coming soon!

ISBN: 978-2-1143-1473-0

Media Contact:

Chelsea Wilkerson

Email: executiveassistant@shakhanandwilkersonlaw.com

Website: www.shakhanandwilkersonlaw.com

Social Media Handles:

Instagram: gadivorce_familylawattorneys

Facebook: Shakhan & Wilkerson Law

TikTok: shakhan_and_wilkersonlaw

Twitter: SandWLawyers

Youtube: shakhanandwilkersonlaw7315

Media Contact
Company Name: Shakhan and Wiklerson Law
Contact Person: Chelsea Wilkerson
Email: Send Email
Country: United States
Website: www.shakhanandwilkersonlaw.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New Book Arms Parents for the Courtroom: “Preparing for the Child Custody War” Offers Vital Strategy, Legal Insight, and Hope

Campaign Launches to Fund Life-Changing Education and Healthcare for 50 Cambodian Children

Boston, MA – A powerful new campaign is rallying global support to give 50 children in rural Cambodia access to vital healthcare, nutritious meals, and a world-class education through the Swiss-Cambodian nonprofit, Smiling Gecko. With a fundraising goal of $195,000 by July 11, 2025, this initiative seeks to transform lives and break the cycle of poverty in one of Southeast Asia’s most underserved regions.

Why Cambodia? Why Now?

Cambodia is still grappling with the aftermath of the Khmer Rouge regime, which decimated over 2 million lives—including its educated class—between 1975 and 1979. Today, nearly 45 years later, access to quality education and basic care remains limited for many in rural communities.

Smiling Gecko is changing that narrative. Inspired by the Swiss education model, this award-winning organization delivers holistic support to vulnerable children: education, vocational training, medical care, and family aid—all on a self-sustaining rural campus.

This summer, Smiling Gecko plans to welcome 50 new students—but urgent funding is needed to make it possible.

“Each child’s full-year support costs $3,900,” said Will G. Foussier, founder of AceUp, a leadership development company partnering with Smiling Gecko. “This includes everything from tuition to daily meals and medical care. Together, we can give these kids not just a classroom, but a chance at a future.”

How You Can Help

Whether it’s a $5 donation or a major philanthropic gift, every contribution moves the campaign closer to its goal. In return, donors can unlock unique perks across five commitment tiers, including:

– Personal letters from children and founders

– Invitations to exclusive fundraising events in New York City

– Executive coaching programs valued up to $12,000

– Luxurious experiences in Cambodia, including private tours and chef dinners

– A classroom named in your honor for $50,000 donors

“This is more than a donation,” added Foussier. “It’s an investment in hope, dignity, and lasting change for an entire generation.”

Your Impact at a Glance

– 50 students sponsored with full tuition, healthcare, meals, and emotional support

– 500+ current students already benefiting from Smiling Gecko’s model- Family-wide change through parent vocational programs and community support

Join the Movement

Donate now at: https://www.gofundme.com/f/donate-to-educate-and-heal-cambodian-children

For press inquiries, interviews, or to request a media kit, please contact:

Name: Will Guillaume Foussier

Email: Will@aceup.com

About Smiling Gecko

Smiling Gecko is a Swiss-Cambodian nonprofit working to combat poverty through sustainable, community-focused development. Founded by photojournalist Hannes Schmid, the organization operates an innovative rural campus offering education, vocational training, healthcare, and housing to hundreds of families.

About AceUp

AceUp is a leadership development platform that empowers individuals and organizations through executive coaching and evidence-based learning. The company supports initiatives that align leadership with global impact.

Media Contact
Company Name: AceUp Smiling Gecko
Contact Person: Will Guillaume Foussie
Email: Send Email
City: Boston
State: Massachusetts
Country: United States
Website: gofund.me/efa0c670

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Campaign Launches to Fund Life-Changing Education and Healthcare for 50 Cambodian Children

Superior Restoration Rebrands as Superior Flood to Strengthen Identity and Expand Disaster Recovery Services Across Southern California

New name reflects company’s core mission while continuing to deliver 24/7 emergency restoration for water, fire, mold, and more

CARLSBAD, Calif. – Superior Restoration, a leading disaster recovery company in Southern California, has officially rebranded to Superior Flood as part of a renewed focus on delivering specialized, high-quality services in water damage, fire restoration, mold remediation, and more.

Founded in 1995, the company has built a strong reputation for rapid response and expert disaster recovery. The new name, Superior Flood, reflects its core mission more clearly and helps distinguish the company from others in the region.

“We’re rebranding to better serve our clients and more clearly communicate what we do best,” said Jody Cisewski, owner of Superior Flood. “This change marks an exciting new chapter for us. While our name is changing, our commitment to quality, professionalism, and 24/7 emergency response remains exactly the same.”

Superior Flood serves residential and commercial clients across San Diego, Orange, and RiversideCounties, offering services that include water extraction, structural drying, fire and smoke remediation, mold removal, and sewage cleanup. Certified by the IICRC, RIA, and CRA, and backed by a seasoned team of restoration professionals, the company brings over two decades of experience to every job.

“Our customers trust us to help restore their homes and businesses in times of crisis,” Cisewski added. “That’s a responsibility we don’t take lightly. With this rebrand, we’re also expanding our team and investing in the latest equipment so we can respond faster and do the job even better.”

In addition to emergency restoration, Superior Flood supports clients through the often-complicated insurance claims process and is a proud member of DKI (Disaster Kleenup International). Their technicians are trained to handle all types of property damage with precision and care.

The company is also positioning itself as a preferred vendor for plumbing companies, property managers, and homeowners’ associations, offering reliability, fast turnaround times, and transparent communication, critical needs in the restoration industry.

With an average on-site response time of 60 minutes or less, Superior Flood continues to live up to its name, offering prompt and professional help when it matters most.

For more information visit https://www.superiorflood.com.

About Superior Flood

Superior Flood is a Southern California-based disaster restoration company providing 24/7 emergency services for water damage, fire and smoke damage, mold removal, and more. Locally owned and operated since 1995, the company is certified by leading industry organizations and serves customers throughout San Diego, Orange, and Riverside Counties.

Media Contact
Company Name: Superior Flood
Contact Person: Jody Cisewski – Owner, Superior Flood
Email: Send Email
Phone: (760) 434-4555
Country: United States
Website: https://www.superiorflood.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Superior Restoration Rebrands as Superior Flood to Strengthen Identity and Expand Disaster Recovery Services Across Southern California

Trufla Revolutionizes Insurance Technology with Comprehensive Digital Solutions for Brokers Across North America.

Trufla, a leading insurtech innovator based in Calgary, is making waves across the insurance industry with its cutting-edge digital tools designed to help insurance brokers and agents scale their business, streamline operations, and enhance their digital presence. With a suite of solutions including truMarket, truWeb, and industry-specific SEO services, Trufla is empowering brokerages throughout the United States and Canada to thrive in an increasingly digital-first world.

“At Trufla, we understand the unique challenges insurance brokers face in today’s fast-moving landscape,” said Sherif Gemayel, CEO of Trufla. “Our mission is to equip brokers with powerful, easy-to-use technology that not only automates workflows but also drives measurable growth. Whether you’re a one-person agency or a multi-branch brokerage, our tools are designed with you in mind.”

A Game-Changing BMS: truMarket

At the heart of Trufla’s offering is truMarket, a BMS built specifically for the insurance industry. truMarket combines lead management, sales automation, and data analytics to help brokers convert more leads and retain more clients.

“truMarket isn’t just a BMS – it’s a growth engine,” said Sherif Gemayel. “It centralizes customer interactions, streamlines follow-ups, and provides actionable insights that let brokers focus on what they do best: building relationships and closing deals.”

Website Design Made for Brokers: truWeb

truWeb is Trufla’s custom website design service tailored exclusively for insurance brokers. With responsive design, modern aesthetics, and built-in lead capture tools, truWeb websites not only look great—they work hard.

“Our clients don’t need to be tech experts to have a high-performing website,” said Diane Jones, VP Customer Success. “truWeb takes care of everything – from UX design to compliance – so brokers can focus on serving their clients.”

Smart SEO for Real Results

Trufla’s SEO services are designed to put brokers on the digital map. Using proven strategies and insurance-specific keyword research, Trufla helps agencies rise through the ranks of Google and reach new clients in their local markets.

“In today’s marketplace, if you’re not visible online, you’re invisible,” said Japneet, SEO Strategist at Trufla. “Our SEO team works hand-in-hand with brokers to make sure they’re found when it matters most.”

Trusted by Hundreds, Growing Every Day

With hundreds of brokerages already on board, Trufla’s impact is being felt across North America. The company’s client-centric approach and deep insurance expertise continue to set it apart in a crowded tech market.

About Trufla

Founded in Calgary, Alberta, Trufla is an award-winning insurtech company offering digital solutions tailored for insurance brokers and agents across North America. By combining deep insurance knowledge with cutting-edge technology, Trufla provides tools that power growth, improve efficiency, and enhance client engagement.

Media Contact
Company Name: Trufla Technology
Contact Person: Tanya Coburn, VP Marketing
Email: Send Email
Phone: 403-516-2717
Country: Canada
Website: www.trufla.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Trufla Revolutionizes Insurance Technology with Comprehensive Digital Solutions for Brokers Across North America.

New Fantasy Novel The Keepers’ New Army by David Stevens Launches to Stirring Acclaim – Everyday Heroes Take the Spotlight

What if greatness didn’t require a bite from a radioactive spider or a wand tucked in a sleeve? In The Keepers’ New Army, debut novelist and seasoned trial lawyer David Stevens asks a bold question: What if simply being good was enough to make you extraordinary?

Officially launched, The Keepers’ New Army is already captivating readers with its fresh take on heroism. Rooted in heartfelt storytelling and powered by vibrant imagination, the novel invites readers into a world where the ultimate power lies not in magic or mutation but in character, courage, and conviction.

At the center of this story is Lake Worthy, a young girl with a bright spirit and a family bound by love, not privilege. On her seventh birthday, life takes an unexpected turn, setting her and her brother Adam on a path that redefines what it means to be chosen. In a universe where chaos brews and ancient powers awaken, The Keepers’ New Army delivers a moving narrative of ordinary children rising to extraordinary challenges.

Inspired by a lunch-table idea shared with his friend Phil Lorenz, Stevens transforms everyday youth into the kind of heroes our world needs—resilient, ethical, and driven by purpose. His own children, Adam and Lake, lend their names and spirit to the main characters, infusing the novel with familial warmth and authenticity.

With its cinematic pacing, memorable characters, and themes of justice, perseverance, and belief in good, The Keepers’ New Army is being hailed as a must-read for middle grade to YA audiences — and for every adult who remembers what it was like to dream of being a hero.

The Keepers’ New Army is now available in print and digital formats at major retailers. Join the movement where the greatest power lies within.

About the Author

David Stevens is a husband, father of two, and a seasoned trial attorney with a passion for storytelling. Drawing from decades of experience in building compelling courtroom narratives, Stevens brings his first novel to life with emotional depth and cinematic detail. He lives and writes in Naperville, Illinois.

Media Contact
Company Name: Book Writing Studios
Contact Person: David Stevens
Email: Send Email
Phone: 63090152922
Address:75 Executive Dr suite 419
City: Aurora
State: Illnois 60504
Country: United States
Website: authordavidstevens.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New Fantasy Novel The Keepers’ New Army by David Stevens Launches to Stirring Acclaim – Everyday Heroes Take the Spotlight

New Study Reveals How Artificial Intelligence Could Transform Post-Surgical Recovery for Millions Worldwide

A groundbreaking new study reveals that artificial intelligence (AI) may hold the key to managing pain, anxiety, and psychological outcomes in surgical patients — offering hope to millions worldwide who suffer from complications after surgery. As health systems grapple with delivering personalized postoperative care at scale, this study synthesizes cutting-edge research to uncover how AI-driven strategies can revolutionize the recovery process across diverse healthcare settings.

The systematic review, titled “Artificial Intelligence (AI)-Driven Approaches to Manage Postoperative Pain, Anxiety, and Psychological Outcomes in Surgical Patients”, was conducted by Sachin Agrawal, Rana Veer Samara Sihman Bharattej Rupavath, Priji Prasad Jalaja, Azhar Ushmani, Aashish Mishra, and Naga Venkata Satish Babu Bodapati. Drawing from a wide body of peer-reviewed studies, the authors examine how AI is being used to predict pain trajectories, identify patients at risk of psychological distress, and deliver personalized interventions that improve post-surgical outcomes.

“This study highlights one of the most exciting frontiers in global medicine,” said Isabelle Gautier, Associate Journalist at Alpine Vision Media. “AI is no longer just a tool for diagnostics — it’s becoming a powerful ally in how patients heal, both physically and emotionally.” Each year, more than 300 million major surgeries are performed globally, with up to 80% of patients experiencing significant pain post-operation and nearly one-third reporting anxiety, depression, or other mental health symptoms. These complications are linked to extended hospital stays, increased opioid use, and billions of dollars in additional care costs — creating a global burden exceeding $60 billion annually.

“By harnessing AI to anticipate and manage these complications, health systems have the potential to not only improve recovery times but also reduce costs on a massive scale,” Gautier noted. “This could be especially transformative in countries where clinical resources are stretched and access to mental health support is limited.” The review highlights how AI models—ranging from machine learning algorithms to wearable-integrated systems—can track patient vitals, interpret emotional indicators, and tailor recovery plans in real-time. These systems also help clinicians make timely decisions on pain management and psychological support, potentially preventing avoidable complications.

“What makes this research particularly compelling is its patient-centered approach,” Gautier added. “It reflects a shift in thinking: from simply treating symptoms to understanding and improving the full patient experience.” Leading global experts in surgical recovery and AI integration—such as Dr. Tinashe Mugabe of Parirenyatwa Group of Hospitals in Zimbabwe, Dr. María Teresa López of Instituto Nacional de Ciencias Médicas y Nutrición in Mexico, and Dr. Nur Aini Sari of Rumah Sakit Cipto Mangunkusumo in Indonesia — have long emphasized the need for intelligent, scalable, and equitable solutions in postoperative care. Their work aligns closely with the themes explored in this review, reinforcing its relevance to international efforts aimed at bridging surgical care gaps through technology.

“The findings speak to the global urgency of more humane, efficient, and technologically enabled recovery systems,” Gautier said. “The authors have created a research framework that can serve both high-tech hospital systems and resource-constrained clinical environments.” Despite its promise, the review also identifies key challenges, including data standardization, ethical governance, and the need for transparent, validated algorithms in real-world settings. The authors urge international collaboration to integrate AI into clinical workflows and scale solutions responsibly.

“We’re at a turning point in postoperative care,” Gautier concluded. “This study offers a clear and credible vision of how AI can help millions heal better, faster, and with dignity — regardless of where they are in the world.”

Reference: Agrawal S, Sihman Bharattej Rupavath R, Prasad Jalaja, et al. (May 16, 2025) Artificial Intelligence (AI)-Driven Approaches to Manage Postoperative Pain, Anxiety, and Psychological Outcomes in Surgical Patients: A Systematic Review. Cureus 17(5): e84226. DOI 10.7759/cureus.84226

Media Contact
Company Name: Alpine Vision Media
Contact Person: Isabelle Gautier
Email: Send Email
Country: Switzerland
Website: https://alpinevisionmedia.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New Study Reveals How Artificial Intelligence Could Transform Post-Surgical Recovery for Millions Worldwide

Cutaneous Lupus Erythematosus Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Gilead Sciences

The Key Cutaneous Lupus Erythematosus Companies in the market include – Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Biogen, Gilead Sciences, Pfizer, Bristol-Myers Squibb, Novartis, Rigel Pharmaceuticals, Merck, and others.

DelveInsight’s “Cutaneous Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cutaneous Lupus Erythematosus, historical and forecasted epidemiology as well as the Cutaneous Lupus Erythematosus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Cutaneous Lupus Erythematosus, offering comprehensive insights into the Cutaneous Lupus Erythematosus revenue trends, prevalence, and treatment landscape. The report delves into key Cutaneous Lupus Erythematosus statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Cutaneous Lupus Erythematosus therapies. Additionally, we cover the landscape of Cutaneous Lupus Erythematosus clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Cutaneous Lupus Erythematosus treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Cutaneous Lupus Erythematosus space.

To Know in detail about the Cutaneous Lupus Erythematosus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cutaneous Lupus Erythematosus Market Forecast

Some of the key facts of the Cutaneous Lupus Erythematosus Market Report:

The Cutaneous Lupus Erythematosus market size was valued ~USD 500 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In March 2025, Merck KGaA’s oral TLR7/8 inhibitor, enpatoran, did not achieve its primary endpoint in a subgroup of patients; however, the company plans to continue its development. During the Q4 earnings call, Merck disclosed that enpatoran failed to meet the British Isles Lupus Assessment Group (BILAG)-Based Composite Lupus Assessment (BICLA) response at 24 weeks in patients with systemic lupus erythematosus (SLE).
The United States holds the largest market size for Cutaneous Lupus Erythematosus, estimated at approximately USD 400 million, surpassing the markets of EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
In 2023, the total diagnosed prevalent cases of Cutaneous Lupus Erythematosus across the 7MM were approximately 800,000 and are expected to rise throughout the forecast period.

Key Cutaneous Lupus Erythematosus Companies: Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Biogen, Gilead Sciences, Pfizer, Bristol-Myers Squibb, Novartis, Rigel Pharmaceuticals, Merck, and others
Key Cutaneous Lupus Erythematosus Therapies: Litifilimab, Daxdilimab, SOTYKTU, Anifrolumab, SAR443122, CC-11050, Litifilimab, Lanraplenib, PF-06823859, Deucravacitinib, KRP20, R932333, M5049, and others
The Cutaneous Lupus Erythematosus market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cutaneous Lupus Erythematosus pipeline products will significantly revolutionize the Cutaneous Lupus Erythematosus market dynamics.
Chronic Cutaneous Lupus Erythematosus has been found to be more prevalent among the diagnosed population compared to other types in the 7MM. In the United States alone, it accounted for approximately 340,000 cases in 2023.
Within the EU4 and the UK, the United Kingdom reported the highest number of diagnosed prevalent cases, followed by France, while Spain had the lowest, with approximately 40,000 cases.
In 2023, the US represented approximately 60% of all diagnosed prevalent cases of Cutaneous Lupus Erythematosus (CLE) across the 7MM.
Within the EU4 and the UK, the UK reported the highest diagnosed prevalence of Cutaneous Lupus Erythematosus (CLE) in 2023, with approximately 80,000 cases, whereas Spain had the lowest, with around 40,000 cases.
Japan recorded approximately 66,000 diagnosed prevalent cases of Cutaneous Lupus Erythematosus (CLE) in 2023.
In 2023, the United States had approximately 478,000 diagnosed prevalent cases of Cutaneous Lupus Erythematosus (CLE).

Cutaneous Lupus Erythematosus Overview

Cutaneous Lupus Erythematosus (CLE) is a form of lupus that primarily affects the skin, causing inflammation and various skin lesions. It can occur independently or as part of systemic lupus erythematosus (SLE). CLE is classified into subtypes, including acute, subacute, and chronic forms, with symptoms like rashes, redness, and scaly patches, often triggered by sunlight exposure. The condition can vary in severity and may leave scars or pigmentation changes. Diagnosis involves clinical evaluation, skin biopsy, and laboratory tests. Treatment typically includes sun protection, topical steroids, immunosuppressants, and antimalarial medications to manage symptoms and prevent flare-ups.

Get a Free sample for the Cutaneous Lupus Erythematosus Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market

Cutaneous Lupus Erythematosus Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cutaneous Lupus Erythematosus Epidemiology Segmentation:

The Cutaneous Lupus Erythematosus market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Diagnosed Prevalent Cases of CLE in the 7MM
Prevalent cases of CLE by Gender in the 7MM
Prevalent Cases of CLE by Type in the 7MM
Prevalent Cases of CLE by Severity in the 7MM
Total Treated Cases of CLE in the 7MM

Download the report to understand which factors are driving Cutaneous Lupus Erythematosus epidemiology trends @ Cutaneous Lupus Erythematosus Epidemiology Forecast

Cutaneous Lupus Erythematosus Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cutaneous Lupus Erythematosus market or expected to get launched during the study period. The analysis covers Cutaneous Lupus Erythematosus market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cutaneous Lupus Erythematosus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cutaneous Lupus Erythematosus Therapies and Key Companies

Litifilimab: Biogen
Daxdilimab: Horizon Therapeutics
SOTYKTU: Bristol–Myers Squibb
Anifrolumab: AstraZeneca
SAR443122: Sanofi
CC-11050: Amgen
Litifilimab: Biogen
Lanraplenib: Gilead Sciences
PF-06823859: Pfizer
Deucravacitinib: Bristol-Myers Squibb
KRP203: Novartis
R932333: Rigel Pharmaceuticals
M5049: Merck

Discover more about therapies set to grab major Cutaneous Lupus Erythematosus market share @ Cutaneous Lupus Erythematosus Treatment Landscape

Cutaneous Lupus Erythematosus Market Strengths

A growing body of research focused on understanding the pathogenesis of CLE, which could lead to the development of more targeted and effective treatment.
The definition of cutaneous lupus is being refined to facilitate diagnostic and research protocols along with improved guidelines. Further, unique features of disease subtypes are being defined.

Cutaneous Lupus Erythematosus Market Opportunities

Research into the pathogenesis of CLE is accelerating, and discoveries are identifying genetic and epigenetic changes. Continued research on mechanisms driving CLE will provide new methods for preventing and treating cutaneous lesions.
The lack of a cure for CLE provides a massive opportunity to launch effective novel therapies and targeted treatments in the emerging pipeline to take over the current market.

Scope of the Cutaneous Lupus Erythematosus Market Report

Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Cutaneous Lupus Erythematosus Companies: Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Biogen, Gilead Sciences, Pfizer, Bristol-Myers Squibb, Novartis, Rigel Pharmaceuticals, Merck, and others
Key Cutaneous Lupus Erythematosus Therapies: Litifilimab, Daxdilimab, SOTYKTU, Anifrolumab, SAR443122, CC-11050, Litifilimab, Lanraplenib, PF-06823859, Deucravacitinib, KRP20, R932333, M5049, and others
Cutaneous Lupus Erythematosus Therapeutic Assessment: Cutaneous Lupus Erythematosus current marketed and Cutaneous Lupus Erythematosus emerging therapies
Cutaneous Lupus Erythematosus Market Dynamics: Cutaneous Lupus Erythematosus market drivers and Cutaneous Lupus Erythematosus market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Cutaneous Lupus Erythematosus Unmet Needs, KOL’s views, Analyst’s views, Cutaneous Lupus Erythematosus Market Access and Reimbursement

To know more about Cutaneous Lupus Erythematosus companies working in the treatment market, visit @ Cutaneous Lupus Erythematosus Clinical Trials and Therapeutic Assessment

Table of Contents

1. Cutaneous Lupus Erythematosus Market Report Introduction

2. Executive Summary for Cutaneous Lupus Erythematosus

3. SWOT analysis of Cutaneous Lupus Erythematosus

4. Cutaneous Lupus Erythematosus Patient Share (%) Overview at a Glance

5. Cutaneous Lupus Erythematosus Market Overview at a Glance

6. Cutaneous Lupus Erythematosus Disease Background and Overview

7. Cutaneous Lupus Erythematosus Epidemiology and Patient Population

8. Country-Specific Patient Population of Cutaneous Lupus Erythematosus

9. Cutaneous Lupus Erythematosus Current Treatment and Medical Practices

10. Cutaneous Lupus Erythematosus Unmet Needs

11. Cutaneous Lupus Erythematosus Emerging Therapies

12. Cutaneous Lupus Erythematosus Market Outlook

13. Country-Wise Cutaneous Lupus Erythematosus Market Analysis (2020–2034)

14. Cutaneous Lupus Erythematosus Market Access and Reimbursement of Therapies

15. Cutaneous Lupus Erythematosus Market Drivers

16. Cutaneous Lupus Erythematosus Market Barriers

17. Cutaneous Lupus Erythematosus Appendix

18. Cutaneous Lupus Erythematosus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cutaneous Lupus Erythematosus Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Biogen, Horizon Therapeutics, Bristol–Myers Squibb, AstraZeneca, Sanofi, Amgen, Gilead Sciences

Spinal Muscular Atrophy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Spinal Muscular Atrophy pipeline constitutes 18+ key companies continuously working towards developing 20+ Spinal Muscular Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Spinal Muscular Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Spinal Muscular Atrophy Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market.

Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report:

Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years.
Spinal Muscular Atrophy companies working in the treatment market are Skyline Therapeutics, Exegenesis Bio, Biogen, GeneCradle Inc., Hangzhou Jiayin Biotech Ltd, Scholar Rock, Inc., Biohaven Pharmaceuticals, Inc, and others, are developing therapies for the Spinal Muscular Atrophy treatment

Emerging Spinal Muscular Atrophy therapies in the different phases of clinical trials are- SKG 0201, Spinal muscular atrophy gene therapy, BIIB115, GC101, EXG001-307, Apitegromab, Talditercept alfa, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years.
In March 2025, Scholar Rock’s spinal muscular atrophy (SMA) treatment demonstrated improvements in muscle function among children under 12 in a key clinical study, yet the results failed to excite investors. The Phase III SAPPHIRE trial (NCT05156320) assessed the safety and effectiveness of apitegromab, a monoclonal antibody designed to enhance muscle growth by targeting and inhibiting the inactive forms of myostatin specifically within skeletal muscle.
In February 2025, A pilot clinical trial suggested that spinal cord stimulation (SCS) may help restore function in patients with spinal muscular atrophy (SMA) by gradually activating dormant motor neurons and enhancing leg muscle strength. Conducted by the University of Pittsburgh School of Medicine (NCT05430113), the study evaluated Medtronic’s Vectris SureScan device in three SMA patients. All participants demonstrated improved mobility, each increasing their distance in the six-minute walk test (6MWT)—a key indicator of muscle endurance—by at least 20 meters after three months of treatment.
In January 2025, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing novel therapies for spinal muscular atrophy (SMA), cardiometabolic conditions, and other serious diseases involving protein growth factors, has announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for apitegromab. This muscle-directed therapy is intended to deliver significant motor function improvement in individuals with SMA who are already receiving SMN-targeted treatments. The company also plans to submit a Marketing Authorisation Application to the European Medicines Agency in the first quarter of 2025.
In January 2025, Analytics firm GlobalData has expressed a positive outlook on the future of Novartis’ gene therapy for spinal muscular atrophy (SMA), onasemnogene abeparvovec (OAV101 IT). The therapy may soon be accessible to a wider patient group, thanks to encouraging results from Novartis’ Phase III STEER trial (NCT05089656), in which the intrathecal version of the treatment successfully met its primary endpoint.
In November 2024, Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative therapies for various rare and common diseases, announced updates on the development programs for taldefgrobep alfa in Spinal Muscular Atrophy (SMA) and obesity.
In November 2024, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to developing innovative therapies for spinal muscular atrophy (SMA), cardiometabolic conditions, and other severe diseases driven by protein growth factors, has announced positive and statistically significant topline results from the pivotal Phase 3 SAPPHIRE trial. These findings highlight the potential of apitegromab to transform the standard of care for SMA patients.
In April 2024, Exegenesis Bio, a fast-expanding global leader in genetic medicine, has shared clinical efficacy and safety findings from its Phase 1/2 trial (EXG001-307) for Spinal Muscular Atrophy (SMA) Type I. The data was presented on May 8, 2024, during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Baltimore, Maryland (poster #627).

Spinal Muscular Atrophy Overview

Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disorder characterized by the progressive degeneration of motor neurons in the spinal cord and brainstem. Motor neurons are nerve cells responsible for controlling voluntary muscle movement. When these motor neurons degenerate, muscles weaken and atrophy, leading to difficulties with movement, muscle weakness, and potentially life-threatening respiratory problems.

Get a Free Sample PDF Report to know more about Spinal Muscular Atrophy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/spinal-muscular-atrophy-sma-pipeline-insight

Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include:

SKG 0201: Skyline Therapeutics
Spinal muscular atrophy gene therapy: Exegenesis Bio
BIIB115: Biogen
GC101: GeneCradle Inc.
EXG001-307: Hangzhou Jiayin Biotech Ltd
Apitegromab: Scholar Rock, Inc.
Talditercept alfa: Biohaven Pharmaceuticals, Inc

Spinal Muscular Atrophy Route of Administration

Spinal Muscular Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Spinal Muscular Atrophy Molecule Type

Spinal Muscular Atrophy Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Spinal Muscular Atrophy Pipeline Therapeutics Assessment

Spinal Muscular Atrophy Assessment by Product Type
Spinal Muscular Atrophy By Stage and Product Type
Spinal Muscular Atrophy Assessment by Route of Administration
Spinal Muscular Atrophy By Stage and Route of Administration
Spinal Muscular Atrophy Assessment by Molecule Type
Spinal Muscular Atrophy by Stage and Molecule Type

DelveInsight’s Spinal Muscular Atrophy Report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies

Some of the key companies in the Spinal Muscular Atrophy Therapeutics Market include:

Key companies developing therapies for Spinal Muscular Atrophy are – Genentech Inc, Chugai Pharmaceutical, Cytokinetics Inc., Ionis Pharmaceuticals Inc., Genzyme Corporation, Novartis International AG, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, PerkinElmer Inc., Pfizer Inc., UW Health, Novo Nordisk A/S, Cure SMA, Boehringer Ingelheim Gmbh, Biogen Inc, F. Hoffmann-La Roche AG, Catalyst Pharmaceutical, Salarius Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Isis Pharmaceuticals Inc., PTC Therapeutics, Natera Inc, AstraZeneca PLC, and others.

Spinal Muscular Atrophy Pipeline Analysis:

The Spinal Muscular Atrophy pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Spinal Muscular Atrophy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment.
Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Spinal Muscular Atrophy drugs and therapies

Spinal Muscular Atrophy Pipeline Market Drivers

Increase in prevalence of Spinal Muscular Atrophy, increasing number of clinical trials and government funding for R&D are some of the important factors that are fueling the Spinal Muscular Atrophy Market.

Spinal Muscular Atrophy Pipeline Market Barriers

However, lack of public knowledge of this rare medical condition, cost associated with the treatment and other factors are creating obstacles in the Spinal Muscular Atrophy Market growth.

Scope of Spinal Muscular Atrophy Pipeline Drug Insight

Coverage: Global
Key Spinal Muscular Atrophy Companies: Skyline Therapeutics, Exegenesis Bio, Biogen, GeneCradle Inc., Hangzhou Jiayin Biotech Ltd, Scholar Rock, Inc., Biohaven Pharmaceuticals, Inc, and others
Key Spinal Muscular Atrophy Therapies: SKG 0201, Spinal muscular atrophy gene therapy, BIIB115, GC101, EXG001-307, Apitegromab, Talditercept alfa, and others
Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies
Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers

Request for Sample PDF Report for Spinal Muscular Atrophy Pipeline Assessment and clinical trials

Table of Contents

1. Spinal Muscular Atrophy Report Introduction

2. Spinal Muscular Atrophy Executive Summary

3. Spinal Muscular Atrophy Overview

4. Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment

5. Spinal Muscular Atrophy Pipeline Therapeutics

6. Spinal Muscular Atrophy Late Stage Products (Phase II/III)

7. Spinal Muscular Atrophy Mid Stage Products (Phase II)

8. Spinal Muscular Atrophy Early Stage Products (Phase I)

9. Spinal Muscular Atrophy Preclinical Stage Products

10. Spinal Muscular Atrophy Therapeutics Assessment

11. Spinal Muscular Atrophy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Spinal Muscular Atrophy Key Companies

14. Spinal Muscular Atrophy Key Products

15. Spinal Muscular Atrophy Unmet Needs

16 . Spinal Muscular Atrophy Market Drivers and Barriers

17. Spinal Muscular Atrophy Future Perspectives and Conclusion

18. Spinal Muscular Atrophy Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spinal Muscular Atrophy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme

From SEO to GEO: geocentric.ai Is Redefining Visibility in the AI Era

New startup helps businesses and creators get found, cited, and trusted by ChatGPT, Perplexity, and other AI engines

May 19, 2025 – Brooklyn NY – The way people search has changed—and so have the rules of visibility. Today’s users aren’t scrolling through ten blue links. They’re getting full answers from AI. That’s why geocentric.ai is launching a revolutionary platform that helps websites and creators show up in those answers—not just in traditional search rankings.

geocentric.ai is pioneering a bold new category called GEO: Generative Engine Optimization. Unlike SEO, which was built for search engines like Google, GEO is designed for generative platforms like ChatGPT, Bing Copilot, Google SGE, and Perplexity.ai. These engines don’t just find pages—they write responses, and only cite the most trusted, high-quality sources. geocentric.ai helps you become one of them.Backed by cutting-edge research and science, the platform uses AI-driven audits, optimization tools, and content strategies proven to increase your chances of being cited by LLMs. In fact, studies show that content optimized with GEO methods—like adding statistics, quotes, and schema—can boost AI visibility by up to 40%.

“With generative engines, there are no ads, no rankings, and no way to pay your way in,” said Arik Rozen, co-founder of geocentric.ai.“You either show up in the answer—or you don’t exist. Businesses using geocentric.ai typically see a major uptick in AI-driven traffic within 3 to 6 months. But without GEO, traffic will decline. This is the new front page of the internet—and you have to earn your place in it.

”Getting listed on AI platforms has never been easier thanks to geocentric.ai’s product suite:

geoTracker lets you monitor your current AI visibility score in seconds.

geoPlanner gives you a personalized, science-backed 6-month plan to improve your visibility and get cited by major AI engines.

And for those who want full support,

geoManager is your complete GEO team—executing the plan, optimizing your content, and working 24/7 to boost your presence across platforms.

With packages starting from free all the way to full-service execution, geocentric.ai is making this new form of optimization accessible to everyone—from solopreneurs to enterprise teams. The startup’s mission is simple: help real people get cited by AI, not buried beneath it.

Media Contact
Company Name: geoCentric AI LLC
Contact Person: Pinny Rozen
Email: Send Email
Phone: 646-995-4013
Address:1820 Ave M #1079
City: Brooklyn
State: NY
Country: United States
Website: https://geocentric.ai/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: From SEO to GEO: geocentric.ai Is Redefining Visibility in the AI Era